Radiopharm Theranostics Limited

ASX:RAD Stock Report

Market Cap: AU$56.5m

Radiopharm Theranostics Valuation

Is RAD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RAD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RAD (A$0.03) is trading below our estimate of fair value (A$1.98)

Significantly Below Fair Value: RAD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RAD?

Key metric: As RAD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RAD. This is calculated by dividing RAD's market cap by their current revenue.
What is RAD's PS Ratio?
PS Ratio30x
SalesAU$1.96m
Market CapAU$56.50m

Price to Sales Ratio vs Peers

How does RAD's PS Ratio compare to its peers?

The above table shows the PS ratio for RAD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average16.5x
ACW Actinogen Medical
7.4x20.0%AU$76.6m
PYC PYC Therapeutics
37.9x15.6%AU$863.2m
PTX Prescient Therapeutics
8.7xn/aAU$32.2m
BDX BCAL Diagnostics
12.2x77.6%AU$39.5m
RAD Radiopharm Theranostics
30x50.2%AU$56.5m

Price-To-Sales vs Peers: RAD is expensive based on its Price-To-Sales Ratio (30x) compared to the peer average (16.5x).

Price to Sales Ratio vs Industry

How does RAD's PS Ratio compare vs other companies in the AU Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
ARX Aroa Biosurgery
3.6x20.1%US$140.28m
IMC Immuron
3.5x59.7%US$11.69m
ATH Alterity Therapeutics
4x25.0%US$10.30m
BNO Bionomics
2.4x-5.3%US$9.52m
RAD 30.0xIndustry Avg. 9.7xNo. of Companies8PS01632486480+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: RAD is expensive based on its Price-To-Sales Ratio (30x) compared to the Australian Biotechs industry average (9.7x).

Price to Sales Ratio vs Fair Ratio

What is RAD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RAD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio30x
Fair PS Ratio0.01x

Price-To-Sales vs Fair Ratio: RAD is expensive based on its Price-To-Sales Ratio (30x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RAD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.027
AU$0.24
+792.5%
55.4%AU$0.40AU$0.073n/a3
Nov ’25AU$0.024
AU$0.25
+953.9%
53.6%AU$0.40AU$0.073n/a3
Oct ’25AU$0.028
AU$0.25
+793.0%
47.3%AU$0.40AU$0.07n/a4
Sep ’25AU$0.037
AU$0.44
+1,080.1%
53.0%AU$0.76AU$0.26n/a3
Aug ’25AU$0.035
AU$0.50
+1,334.7%
39.9%AU$0.75AU$0.26n/a3
Jul ’25AU$0.038
AU$0.50
+1,221.4%
39.9%AU$0.75AU$0.26n/a3
Jun ’25AU$0.032
AU$0.38
+1,090.2%
31.6%AU$0.50AU$0.26n/a2
May ’25AU$0.04
AU$0.48
+1,099.8%
45.7%AU$0.70AU$0.26n/a2
Apr ’25AU$0.056
AU$0.48
+757.0%
45.7%AU$0.70AU$0.26n/a2
Jan ’25AU$0.074
AU$0.47
+533.1%
47.5%AU$0.69AU$0.25n/a2
Dec ’24AU$0.074
AU$0.48
+547.6%
46.2%AU$0.70AU$0.26n/a2
Nov ’24AU$0.086
AU$0.48
+457.2%
46.2%AU$0.70AU$0.26AU$0.0242
Oct ’24AU$0.12
AU$0.48
+299.1%
46.3%AU$0.70AU$0.26AU$0.0282
Sep ’24AU$0.095
AU$0.47
+399.6%
47.8%AU$0.70AU$0.25AU$0.0372
Aug ’24AU$0.095
AU$0.47
+399.6%
47.8%AU$0.70AU$0.25AU$0.0352
Jul ’24AU$0.10
AU$0.47
+352.0%
47.8%AU$0.70AU$0.25AU$0.0382
Jun ’24AU$0.14
AU$0.50
+271.3%
50.2%AU$0.75AU$0.25AU$0.0322
May ’24AU$0.20
AU$0.50
+151.3%
49.8%AU$0.75AU$0.25AU$0.042
Apr ’24AU$0.16
AU$0.50
+209.3%
49.8%AU$0.75AU$0.25AU$0.0562

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

AVITA Medical

US$313.4m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.71

7D

4.8%

1Y

-2.4%

Medical Developments International

AU$48.4m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.42

7D

-3.4%

1Y

-44.4%

AVITA Medical

US$326.0m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.79

7D

3.0%

1Y

8.9%